Welcome

Hedge Fund-Pick Arcturus Gambles on a One-Shot Covid Vaccine (1)

Oct. 8, 2020, 2:06 PM

Two-and-a-half years ago Joseph Payne was ousted from Arcturus Therapeutics Holdings Inc., the biotech company he helped found, by what he calls a “dysfunctional board.” Four months later he was back at the helm and the now $1.2 billion firm is racing to push out a Covid-19 vaccine alongside the world’s leading contenders.

The contentious transfer of power came after the previously private Arcturus gained access to the public markets in a reverse merger with Alcobra, a struggling biotech. Today, Arcturus’s goal is to develop a potent low-dose one-shot messenger RNA Covid-19 inoculation.

Like other vaccine and drug ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.